As the voice of the research-based pharmaceutical industry in the UK, we work to improve the UK as a competitive place for the pharmaceutical industry. We do this by engaging with Government and regulators on policy issues of interest to the pharmaceutical industry.
Through partnerships and a coherent policy framework across issues relating to research, development, manufacturing, regulation, market conditions and patient access, we believe that the industry will be able to bring leading-edge treatments and technologies to patients, whilst maintaining the UK’s global leadership in life sciences.
We, therefore, meet regularly with parliamentarians from all parties to inform them about the industry and its contribution to the health and wealth of the country, as well as to provide expert input to policy discussions. We work with ministers, officials and parliamentarians across Government and the Houses of Parliament to seek ways to improve patient access to treatment and healthcare outcomes and to support a vibrant pharmaceutical industry in the UK.
We provide a joint-secretarial support to the All Party Parliamentary Group for Life Sciences, which provides a platform for parliamentarians from all parties to explore issues and policies of common interest.
Our policy and parliamentary work includes providing briefings on policy issues, giving evidence to select committees and responding to Government consultations.
For more information about the policy and parliamentary work of the ABPI, please contact email@example.com.
The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues including medicines regulation, UK and EU trading relationships, access to talent, and the future of UK science.
On 27 November 2017, the Government launched its Industrial Strategy white paper. The Association of the British Pharmaceutical Industry (ABPI) – the trade group for the pharmaceutical industry in the UK – have welcomed the government's roadmap for business.